Welcome to our dedicated page for Global Medical SEC filings (Ticker: GMRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chiron Real Estate Inc., formerly Global Medical REIT Inc., files SEC reports documenting the public-company record of its net-lease medical REIT business and operating partnership structure. Its filings cover operating and financial results, earnings supplements, dividend and preferred-stock disclosures, shareholder voting matters, board composition and governance events.
Material-event filings also document capital-structure arrangements such as senior unsecured note facilities, master note and guaranty agreements, and related operating partnership obligations. The record includes the completed corporate name change from Global Medical REIT to Chiron Real Estate and associated issuer-status disclosures.
GMRE’s Q2 2025 10-Q shows modest top-line growth offset by higher financing costs. Rental revenue rose 10.7% YoY to $37.9 m, lifting total revenue to $38.0 m. Operating expense inflation (+13%) and an 15% jump in interest expense limited operating income to $0.4 m (vs. $1.4 m LY). Net income turned positive at $0.6 m, yet after $1.5 m preferred dividends common shareholders posted a $0.8 m loss (-$0.01/sh).
Balance sheet leverage increased. Net real-estate investment grew $42 m to $1.20 b after acquiring five facilities for $79.7 m and selling three for $9.1 m gains. Credit-facility borrowings expanded $67 m to $699 m, pushing total liabilities to $772 m (+10%). Equity fell 6% to $525 m, driven by dividend distributions and an $8.2 m OCI hit from falling swap values. Cash flow from operations covered common and preferred dividends ($34.4 m OCF vs. $33.4 m payouts). Management flags $24.6 m of committed cap-ex (≈$12.6 m in next 12 mo).
Key trends: 1) revenue growth from acquisitions continues; 2) elevated debt and rising SOFR expose earnings to rate risk despite hedges; 3) dividend remains higher than GAAP earnings but covered by FFO proxy cash flow; 4) active capital recycling—three small Q1-Q2 sales and a 12.5% JV stake launched in late-2024.
Global Medical REIT (NYSE:GMRE) Form 4 discloses that newly appointed CEO and President Mark Okey Decker Jr. purchased 160,000 common shares on 24-25 June 2025 at a weighted average price of about $6.52, committing roughly $1.0 million of personal capital. Following the transactions, he directly owns 160,000 shares.
On 23 June 2025 he also received 158,730 Long-Term Incentive Plan (LTIP) units, exchangeable one-for-one for common stock after vesting on the third anniversary of grant.
- Transaction code: P (open-market purchases)
- Ownership form: Direct
- No Rule 10b5-1 plan indicated
The >$1 million insider buy by the CEO is a potentially positive signal of management confidence and tighter alignment with shareholder interests.
Form 3 filing overview: Global Medical REIT Inc. (GMRE) submitted an Initial Statement of Beneficial Ownership (Form 3) on 25 June 2025 for Mark Okey Decker Jr., who is listed as both Director and President & CEO.
Key details
- Date of event: 23 June 2025
- Securities owned: None – the filing explicitly states “No securities are beneficially owned.”
- Signatory: /s/ Jamie Barber acting under Power of Attorney dated 23 June 2025.
The document satisfies Section 16(a) initial reporting requirements and indicates the new executive currently holds zero GMRE common shares or derivative securities, leaving open the possibility of future insider acquisitions that would require subsequent Form 4 disclosures.
Global Medical REIT Inc. (NYSE: GMRE) filed an 8-K disclosing a CEO transition effective 23 Jun 2025. Jeffrey M. Busch has been removed as Chief Executive Officer and President and will remain non-executive Chairman. The Board simultaneously appointed Mark O. Decker, Jr. (age 49) as CEO, President and Board member, expanding the Board from seven to eight seats.
The filing provides a detailed three-year employment agreement between Inter-American Management LLC and Mr. Decker:
- Base salary: $700,000 per year.
- Target annual cash bonus: ≥100 % of base salary, prorated for 2025 (60 % cash / 40 % LTIP Units).
- Equity incentives: one-time $1 million LTIP award on the Effective Date; $1.2 million target LTIP award for 2026.
- Relocation stipend: $75,000.
Severance for a "Qualifying Termination" equals 2× (base salary + greater of target or prior-year bonus), pro-rated bonus, accelerated vesting of equity, and up to 18 months of subsidized health coverage. Enhanced benefits (up to 3× multiplier) apply upon qualifying terminations linked to a change in control. Definitions of "good reason" and "cause" are standard for REIT executives.
Mr. Decker’s prior roles include Managing Partner at Proterra Value Investors (2023-2025) and CEO/CIO of Centerspace (NYSE: CSR, 2017-2023). The filing states no family relationships or related-party transactions.